Diphenhydramine hydrochloride; naproxen sodium - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for diphenhydramine hydrochloride; naproxen sodium and what is the scope of patent protection?
Diphenhydramine hydrochloride; naproxen sodium
is the generic ingredient in two branded drugs marketed by Bayer Hlthcare, Amneal Pharms Co, Corepharma, Granules, P And L, and Perrigo R And D, and is included in six NDAs. Additional information is available in the individual branded drug profile pages.Twenty-two suppliers are listed for this compound.
Summary for diphenhydramine hydrochloride; naproxen sodium
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 6 |
NDAs: | 6 |
Finished Product Suppliers / Packagers: | 22 |
Clinical Trials: | 9 |
DailyMed Link: | diphenhydramine hydrochloride; naproxen sodium at DailyMed |
Recent Clinical Trials for diphenhydramine hydrochloride; naproxen sodium
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Ciusss de L'Est de l'Île de Montréal | N/A |
Alphacait, LLC | Phase 2 |
Haining Health-Coming Biotech Co., Ltd. | Phase 2 |
See all diphenhydramine hydrochloride; naproxen sodium clinical trials
Pharmacology for diphenhydramine hydrochloride; naproxen sodium
Drug Class | Histamine-1 Receptor Antagonist Nonsteroidal Anti-inflammatory Drug |
Mechanism of Action | Cyclooxygenase Inhibitors Histamine H1 Receptor Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for diphenhydramine hydrochloride; naproxen sodium
US Patents and Regulatory Information for diphenhydramine hydrochloride; naproxen sodium
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amneal Pharms Co | NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE | diphenhydramine hydrochloride; naproxen sodium | TABLET;ORAL | 209726-001 | Oct 23, 2018 | OTC | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Perrigo R And D | NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE | diphenhydramine hydrochloride; naproxen sodium | TABLET;ORAL | 208499-001 | May 10, 2019 | OTC | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Corepharma | NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE | diphenhydramine hydrochloride; naproxen sodium | TABLET;ORAL | 211830-001 | Aug 22, 2019 | OTC | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.